Skip to main content
  • Five-Year Results of the Bioflow-III Registry: Real-World Experience with a Biodegradable Polymer Sirolimus-Eluting Stent

    Highlights

    • Prospective international registry including 1738 Orsiro-treated lesions
    • Subgroups: diabetics, small vessels, chronic total occlusion, myocardial infarction
    • 5-year target lesion failure of 10.0% [95% CI: 8.4; 13.5] in the overall population
    • 5-year target lesion failure of 1.8% to 14.0% in subgroups
    • 5-year definite stent thrombosis ≤0.5% in the overall population and in subgroups

    Abstract

    Purpose

    We aimed to assess long-term safety and performance of the Orsiro sirolimus-eluting coronary stent with biodegradable polymer in a large unselected population and in pre-specified subgroups.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details